FDA approves new warnings on anemia drugs

Nov 09, 2007

The U.S. Food and Drug Administration has approved revised warnings and labeling changes for the anemia drugs Aranesp, Epogen and Procrit.

The warnings on the erythropoiesis-stimulating agents address the risks that the drugs pose to patients with cancer or chronic kidney failure, the FDA said Friday in a release.

The FDA said the labeling changes include a statement that symptoms of anemia, fatigue and quality of life haven't been shown to improve in patients with cancer who are treated with ESAs.

Epogen, Procrit and Aranesp are approved to treat anemia in patients with chronic kidney failure and anemia caused by chemotherapy in certain patients with cancer. Epogen and Procrit are also approved for use in certain patients with anemia who are scheduled to undergo major surgery and for the treatment of anemia caused by zidovudine therapy in HIV patients.

The new boxed warnings emphasize that ESAs caused tumor growth and shortened survival in patients with advanced breast, head and neck, lymphoid and non-small cell lung cancer when they received a dose that attempted to achieve a hemoglobin level of 12 grams per deciliter or greater, the release said.

Copyright 2007 by United Press International

Explore further: A look at the growing use of synthetic drugs

add to favorites email to friend print save as pdf

Related Stories

New jigsaw piece for the repair of DNA crosslinks

May 27, 2014

Environmental influences such as ionizing radiation, intense heat or various chemical substances damage the DNA constantly. Only thanks to efficient repair systems can mutations – changes in the DNA – ...

Recommended for you

A look at the growing use of synthetic drugs

45 minutes ago

In recent years, hundreds of new synthetic recreational drugs have emerged – drugs that neither the general public nor the scientific community know very much about. Many of these new synthetic drugs – ...

Breakthrough to take the pain out of catheters

Mar 05, 2015

A new pharmaceutical product that could significantly improve quality of life for catheter users all over the world is to be developed by Queen's University Belfast after it won a national award.

FDA warning: men's testosterone drugs overused (Update)

Mar 03, 2015

The Food and Drug Administration is warning doctors against over-prescribing testosterone-boosting drugs for men, saying the popular treatments have not been established as safe or effective for common age-related ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.